Close

Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound Dec 13, 2011 07:28PM
Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound Dec 13, 2011 07:00PM
New Data Show Investigational Compound Dapagliflozin When Added to Glimepiride Maintained Reductions in Blood Sugar Levels in Adults with Type 2 Diabetes Over 48 Weeks of Treatment Dec 8, 2011 03:30AM
Bristol-Myers Squibb Announces Dividend Increase Dec 6, 2011 05:05PM
Bristol-Myers Squibb Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals for Phase II Combination Study in Patients Chronically Infected with Hepatitis C Dec 2, 2011 07:30AM


Nov 30, 2011 10:00AM Alvin Ailey American Dance Theater Premieres Home, A New Work Inspired by the Winning Photos and Essays from the 2011 REYATAZ® (atazanavir sulfate) “Fight HIV Your Way” Contest, an Initiative of
Nov 29, 2011 07:30AM FDA Accepts ELIQUIS® (apixaban) New Drug Application for Review for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
Nov 17, 2011 01:26PM Lpath Gets Attention From Pfizer and Analysts as a Potential Buy-Out Candidate
Nov 16, 2011 04:00PM Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients with Type 2 Diabetes
Nov 13, 2011 08:01AM New Data Presented On Phase 3 Trial Of ELIQUIS® (apixaban) In The Prevention Of Venous Thromboembolism In Patients With Acute Medical Illness
Nov 11, 2011 09:05AM Bristol-Myers Squibb Signs New Agreement to Expand Access to Reyataz® (atazanavir sulfate) in Brazil
Nov 8, 2011 12:00PM 12-Week On-Treatment Results from Large Phase IIb Study (COMMAND-1) of Bristol-Myers Squibb’s NS5A Inhibitor Daclatasvir Support Anti-HCV Activity and Safety Profile Observed in Earlier Studies
Nov 8, 2011 11:00AM Phase IIIb Comparison of BARACLUDE® (entecavir) Monotherapy Versus BARACLUDE Plus Tenofovir Combination Shows No Statistical Difference Between Study Arms
Nov 7, 2011 06:30PM All-Oral Treatment Regimen of Bristol-Myers Squibb’s Investigational NS5A and NS3 Inhibitors Achieved 90% Sustained Virologic Response (SVR12) in Phase II Study Sentinel Cohort of Genotype 1b Null R
Nov 4, 2011 07:00AM New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1
Nov 4, 2011 07:00AM New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1
Nov 3, 2011 09:00AM New Investigational Data on ORENCIA® (abatacept) to be Presented at the American College of Rheumatology Annual Scientific Meeting
Nov 3, 2011 07:30AM ASLAN Pharmaceuticals and Bristol-Myers Squibb Enter Innovative Partnership to License and Develop Investigational Oncology Compound
Nov 2, 2011 10:00AM Bristol-Myers Squibb to Present at Credit Suisse Health Care Conference
Oct 27, 2011 07:30AM Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development
Oct 26, 2011 04:05PM U.S. Food and Drug Administration Extends Action Date for Dapagliflozin by Three Months
Oct 26, 2011 08:30AM Bristol-Myers Squibb and Gilead Sciences Announce Licensing Agreement for Development and Commercialization of New Fixed-Dose Combination Pill for People Living with HIV